Germany Compounding Chemotherapy Market

ID: MRFR/Pharma/51699-HCR
200 Pages
Rahul Gotadki
Last Updated: February 06, 2026
Germany Compounding Chemotherapy Market Research Report By Dose (Chemotherapeutic, Non-Chemotherapeutics), By Delivery Method (Gravimetric Automated Compounding Device, Volumetric Automated Compounding Device), By Sterility (Sterile, Non-Sterile), and By Technology (With Robotic Arms, Without Robotic Arms) - Growth & Industry Forecast 2025 To 2035
Download PDF ×

We do not share your information with anyone. However, we may send you emails based on your report interest from time to time. You may contact us at any time to opt-out.

Germany Compounding Chemotherapy Market

Market Size

Forecast Period2025 - 2035
CAGR (2025 - 2035)5.95%
2024 Market Size$ 39.75 Million
2025 Market Size$ 42.12 Million
2035 Market Size$ 75.05 Million

Key Players

Fresenius Kabi
Baxter International
Civica Rx
PharMEDium Services
Compounding Pharmacy of America
Avella Specialty Pharmacy
Opportunities
  • Rising Cancer Incidence
  • Increased Focus on Patient-Centric Care
  • Advancements in Pharmaceutical Compounding
  1. 1 SECTION I: EXECUTIVE SUMMARY AND KEY HIGHLIGHTS
    1. 1.1 EXECUTIVE SUMMARY
      1. 1.1.1 Market Overview
      2. 1.1.2 Key Findings
      3. 1.1.3 Market Segmentation
      4. 1.1.4 Competitive Landscape
      5. 1.1.5 Challenges and Opportunities
      6. 1.1.6 Future Outlook
  2. 2 SECTION II: SCOPING, METHODOLOGY AND MARKET STRUCTURE
    1. 2.1 MARKET INTRODUCTION
      1. 2.1.1 Definition
      2. 2.1.2 Scope of the study
        1. 2.1.2.1 Research Objective
        2. 2.1.2.2 Assumption
        3. 2.1.2.3 Limitations
    2. 2.2 RESEARCH METHODOLOGY
      1. 2.2.1 Overview
      2. 2.2.2 Data Mining
      3. 2.2.3 Secondary Research
      4. 2.2.4 Primary Research
        1. 2.2.4.1 Primary Interviews and Information Gathering Process
        2. 2.2.4.2 Breakdown of Primary Respondents
      5. 2.2.5 Forecasting Model
      6. 2.2.6 Market Size Estimation
        1. 2.2.6.1 Bottom-Up Approach
        2. 2.2.6.2 Top-Down Approach
      7. 2.2.7 Data Triangulation
      8. 2.2.8 Validation
  3. 3 SECTION III: QUALITATIVE ANALYSIS
    1. 3.1 MARKET DYNAMICS
      1. 3.1.1 Overview
      2. 3.1.2 Drivers
      3. 3.1.3 Restraints
      4. 3.1.4 Opportunities
    2. 3.2 MARKET FACTOR ANALYSIS
      1. 3.2.1 Value chain Analysis
      2. 3.2.2 Porter's Five Forces Analysis
        1. 3.2.2.1 Bargaining Power of Suppliers
        2. 3.2.2.2 Bargaining Power of Buyers
        3. 3.2.2.3 Threat of New Entrants
        4. 3.2.2.4 Threat of Substitutes
        5. 3.2.2.5 Intensity of Rivalry
      3. 3.2.3 COVID-19 Impact Analysis
        1. 3.2.3.1 Market Impact Analysis
        2. 3.2.3.2 Regional Impact
        3. 3.2.3.3 Opportunity and Threat Analysis
  4. 4 SECTION IV: QUANTITATIVE ANALYSIS
    1. 4.1 Chemicals and Materials, BY Dose (USD Million)
      1. 4.1.1 Chemotherapeutic
      2. 4.1.2 Non-Chemotherapeutics
    2. 4.2 Chemicals and Materials, BY Delivery Method (USD Million)
      1. 4.2.1 Gravimetric Automated Compounding Device
      2. 4.2.2 Volumetric Automated Compounding Device
    3. 4.3 Chemicals and Materials, BY Sterility (USD Million)
      1. 4.3.1 Sterile
      2. 4.3.2 Non-Sterile
    4. 4.4 Chemicals and Materials, BY Technology (USD Million)
      1. 4.4.1 With Robotic Arms
      2. 4.4.2 Without Robotic Arms
  5. 5 SECTION V: COMPETITIVE ANALYSIS
    1. 5.1 Competitive Landscape
      1. 5.1.1 Overview
      2. 5.1.2 Competitive Analysis
      3. 5.1.3 Market share Analysis
      4. 5.1.4 Major Growth Strategy in the Chemicals and Materials
      5. 5.1.5 Competitive Benchmarking
      6. 5.1.6 Leading Players in Terms of Number of Developments in the Chemicals and Materials
      7. 5.1.7 Key developments and growth strategies
        1. 5.1.7.1 New Product Launch/Service Deployment
        2. 5.1.7.2 Merger & Acquisitions
        3. 5.1.7.3 Joint Ventures
      8. 5.1.8 Major Players Financial Matrix
        1. 5.1.8.1 Sales and Operating Income
        2. 5.1.8.2 Major Players R&D Expenditure. 2023
    2. 5.2 Company Profiles
      1. 5.2.1 Fresenius Kabi (DE)
        1. 5.2.1.1 Financial Overview
        2. 5.2.1.2 Products Offered
        3. 5.2.1.3 Key Developments
        4. 5.2.1.4 SWOT Analysis
        5. 5.2.1.5 Key Strategies
      2. 5.2.2 Baxter International (US)
        1. 5.2.2.1 Financial Overview
        2. 5.2.2.2 Products Offered
        3. 5.2.2.3 Key Developments
        4. 5.2.2.4 SWOT Analysis
        5. 5.2.2.5 Key Strategies
      3. 5.2.3 Civica Rx (US)
        1. 5.2.3.1 Financial Overview
        2. 5.2.3.2 Products Offered
        3. 5.2.3.3 Key Developments
        4. 5.2.3.4 SWOT Analysis
        5. 5.2.3.5 Key Strategies
      4. 5.2.4 PharMEDium Services (US)
        1. 5.2.4.1 Financial Overview
        2. 5.2.4.2 Products Offered
        3. 5.2.4.3 Key Developments
        4. 5.2.4.4 SWOT Analysis
        5. 5.2.4.5 Key Strategies
      5. 5.2.5 Compounding Pharmacy of America (US)
        1. 5.2.5.1 Financial Overview
        2. 5.2.5.2 Products Offered
        3. 5.2.5.3 Key Developments
        4. 5.2.5.4 SWOT Analysis
        5. 5.2.5.5 Key Strategies
      6. 5.2.6 Avella Specialty Pharmacy (US)
        1. 5.2.6.1 Financial Overview
        2. 5.2.6.2 Products Offered
        3. 5.2.6.3 Key Developments
        4. 5.2.6.4 SWOT Analysis
        5. 5.2.6.5 Key Strategies
      7. 5.2.7 PillPack (US)
        1. 5.2.7.1 Financial Overview
        2. 5.2.7.2 Products Offered
        3. 5.2.7.3 Key Developments
        4. 5.2.7.4 SWOT Analysis
        5. 5.2.7.5 Key Strategies
      8. 5.2.8 Onco360 (US)
        1. 5.2.8.1 Financial Overview
        2. 5.2.8.2 Products Offered
        3. 5.2.8.3 Key Developments
        4. 5.2.8.4 SWOT Analysis
        5. 5.2.8.5 Key Strategies
    3. 5.3 Appendix
      1. 5.3.1 References
      2. 5.3.2 Related Reports
  6. 6 LIST OF FIGURES
    1. 6.1 MARKET SYNOPSIS
    2. 6.2 GERMANY MARKET ANALYSIS BY DOSE
    3. 6.3 GERMANY MARKET ANALYSIS BY DELIVERY METHOD
    4. 6.4 GERMANY MARKET ANALYSIS BY STERILITY
    5. 6.5 GERMANY MARKET ANALYSIS BY TECHNOLOGY
    6. 6.6 KEY BUYING CRITERIA OF CHEMICALS AND MATERIALS
    7. 6.7 RESEARCH PROCESS OF MRFR
    8. 6.8 DRO ANALYSIS OF CHEMICALS AND MATERIALS
    9. 6.9 DRIVERS IMPACT ANALYSIS: CHEMICALS AND MATERIALS
    10. 6.10 RESTRAINTS IMPACT ANALYSIS: CHEMICALS AND MATERIALS
    11. 6.11 SUPPLY / VALUE CHAIN: CHEMICALS AND MATERIALS
    12. 6.12 CHEMICALS AND MATERIALS, BY DOSE, 2024 (% SHARE)
    13. 6.13 CHEMICALS AND MATERIALS, BY DOSE, 2024 TO 2035 (USD Million)
    14. 6.14 CHEMICALS AND MATERIALS, BY DELIVERY METHOD, 2024 (% SHARE)
    15. 6.15 CHEMICALS AND MATERIALS, BY DELIVERY METHOD, 2024 TO 2035 (USD Million)
    16. 6.16 CHEMICALS AND MATERIALS, BY STERILITY, 2024 (% SHARE)
    17. 6.17 CHEMICALS AND MATERIALS, BY STERILITY, 2024 TO 2035 (USD Million)
    18. 6.18 CHEMICALS AND MATERIALS, BY TECHNOLOGY, 2024 (% SHARE)
    19. 6.19 CHEMICALS AND MATERIALS, BY TECHNOLOGY, 2024 TO 2035 (USD Million)
    20. 6.20 BENCHMARKING OF MAJOR COMPETITORS
  7. 7 LIST OF TABLES
    1. 7.1 LIST OF ASSUMPTIONS
  8. 7.1.1
    1. 7.2 Germany MARKET SIZE ESTIMATES; FORECAST
      1. 7.2.1 BY DOSE, 2025-2035 (USD Million)
      2. 7.2.2 BY DELIVERY METHOD, 2025-2035 (USD Million)
      3. 7.2.3 BY STERILITY, 2025-2035 (USD Million)
      4. 7.2.4 BY TECHNOLOGY, 2025-2035 (USD Million)
    2. 7.3 PRODUCT LAUNCH/PRODUCT DEVELOPMENT/APPROVAL
  9. 7.3.1
    1. 7.4 ACQUISITION/PARTNERSHIP
  10. 7.4.1

Germany Chemicals and Materials Market Segmentation

Chemicals and Materials By Dose (USD Million, 2025-2035)

  • Chemotherapeutic
  • Non-Chemotherapeutics

Chemicals and Materials By Delivery Method (USD Million, 2025-2035)

  • Gravimetric Automated Compounding Device
  • Volumetric Automated Compounding Device

Chemicals and Materials By Sterility (USD Million, 2025-2035)

  • Sterile
  • Non-Sterile

Chemicals and Materials By Technology (USD Million, 2025-2035)

  • With Robotic Arms
  • Without Robotic Arms